The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Jacqueline S. GarciaDuring the EHA 2022 Congress, the MDS Hub was pleased to speak with Jacqueline Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How could venetoclax combinations improve outcome in high-risk MDS?
How could venetoclax combinations improve outcome in high-risk MDS?
Garcia begins by discussing current ongoing trials investigating venetoclax combinations, including the phase III VERONA study. Garcia goes on to talk about the use of venetoclax with HMA therapy for patients with relapsed/refractory disease, and the response and remission rates of different combinations.